Study #2023-1008
A phase I study investigating the combination of the ziftomenib, venetoclax and azacitidine in pediatric relapsed and refractory acute leukemias
MD Anderson Study Status
Enrolling
Treatment Agent
Ziftomenib, Venetoclax, Azacitidine
Description
To find the highest safe dose of ziftomenib that can be combined with venetoclax and azacitidine in pediatric participants with acute leukemia that has certain types of genetic mutations (changes).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Refractory Acute Leukemia, Pediatric Relapsed
Study phase:
Phase I
Physician name:
David McCall
Department:
Pediatrics
For general questions about clinical trials:
1-844-853-9500
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.